Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01
Alexander Wilkinson, Eric Lattmann, Carla B. Roces, Gabriel Pedersen, Dennis Christensen, Yvonne Perrie
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01'. Together they form a unique fingerprint.